Bofanglutide Weekly or Biweekly Dosing Outperformed Semaglutide in Reducing HbA1c for Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, often leading to severe complications. While existing glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide effectively improve glycemic control and body weight, there remains a need for novel agents offering enhanced efficacy, alternative dosing frequencies, or improved tolerability profiles. Developing new GLP-1RAs with flexible dosing, such as biweekly administration, could improve patient adherence and expand treatment options for managing HbA1c levels and associated metabolic dysregulation. This study investigates bofanglutide as a potential new therapeutic option.

This Phase 2b, multicenter, randomized, open-label, active-controlled trial enrolled 272 Chinese adults with T2DM (glycated hemoglobin A1c [HbA1c] 7.0%-11.0%). Participants were randomized 1:1:1:1:1 into five treatment groups: bofanglutide titrated to 12, 18, or 24 mg biweekly (Q2W); bofanglutide titrated to 24 mg once weekly (QW); or semaglutide titrated to 1 mg QW. The primary endpoint was the change in HbA1c level from baseline to week 24, with secondary efficacy and safety endpoints also assessed.